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The current study demonstrated that three preopera-
tive clinical variables—number of medications, diastolic BP
90 mmHg, and clonidine use—may be useful predictors
of BP response to RAS. Patients with none of these predic-
tors present before stenting are highly unlikely to respond
to RAS with improved BP, having a response rate of 1.5% in
our experience. With one predictor, the BP response rate
rose to 45%. Patients with two or more predictors have at
least a 76% probability of BP response. Kidney volume may
help in discriminating responders from nonresponders
among those patients with 3-drug hypertension. Being
cognizant of these predictors of BP response may assist
clinicians in patient selection and provide more concrete
data with which to counsel patients on the likely outcomes
for RAS.
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Dr Julie Ann Freischlag (Baltimore, Md). When you looked
back at the 97 patients that you studied and reviewed all the factors
we thought we knew to be true — medications, creatinine, kidney
size — how are you changing how you choose those patients who
should undergo renal artery intervention? How did you put it all
together? Have you changed what you have done now that you
look forward?
Dr Gregory Modrall. I think we have a very heterogeneous
group of surgeons and radiologists. Clearly, the practice patterns
are different between our radiologists and our surgeons. The
radiologists tend to get patients who were referred from the
outside of the facility. They are asked to provide the technical
expertise of performing renal artery stenting and they do precisely
that.
In our vascular surgery practice, we are more commonly asked
our opinion on the probability of benefit for renal artery stenting.
Because these are new data that have not been externally validated,he unpredictability of outcomes for renal artery stenting.My hope
s that with the use of better predictors of outcome, we can obtain
etter clinical outcomes and people will again feel more comfort-
ble referring patients to us for renal artery stenting.
Dr Freischlag. Having a third get better probably was a little
obering, because you were hoping for a higher number.
Dr Modrall. I would challenge anyone to look at their own
esults. Often, the reality is not as optimistic as one would have
redicted. I think this really speaks to the need for reliable markers
f a favorable outcome from stenting.
Dr Anil Hingorani (Brooklyn, NY). Did you actually look at
he kidney itself in terms of perfusion to the kidney and did you
easure resistive indexes or perfusion to the cortex or such num-
ers?
Dr Modrall. We attempted to look at renal perfusion with the
cans, but there is such a variation in imaging technique between
cans that I don’t find that to be a useful endeavor. Most of the
atients who had renal duplexes performed at referring institutions
r not at all, so the resistive indices were often lacking on this study.
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resistive indexes with kidney volumes.
Dr Wilhelm Sandmann (Düsseldorf, Germany). Your mea-
surement probably looks a little bit too simple to be the answer to
the question: Who should undergo revascularization and who
should not? I think it was 8 years ago that Rademacher from the
Medical School of Hannover published a paper in the New Eng-
land Journal of Medicine showing that there is a threshold if you
measure or calculate the resistive index. Somy question is, How do
your data correspond to the resistive index properly measured in all
segments of both kidneys?
Dr Modrall. As you are probably aware, some centers have
found utility in measuring resistive indexes, but resistive indexes
have been lacking in predictive value in other institutions. Unfor-
tunately, in the current series, only a minority of patients had
resistive indexes measured, so I can’t correlate the resistive indexes
to the kidney volume size. Ideally, both should be obtained and
these data should be used in tandem in the decision-making
process.
Dr John Jeb Hallett (Charleston, SC). Greg, this is a won-
derful paper in terms of giving us something to use in practice. I
have two questions: Are you using this volume measurement
regularly now, and is that done by radiology or done by you? And
the second is, are these recommendations applicable to your sur-
gical revascularization for renal artery disease?
Dr Modrall: This is such a new finding, we have incorporated
it into our practice. We began this study with the intent of doing
computed tomography-based automatic measurements of kidney
volume. And it turns out that when you use some of the volume-
painting or volume-measuring programs in the software, it is
neither automatic nor without considerable subjectivity in the
process. For that reason, we opted to use the volume-estimating
technique we described in this paper. One of the coauthors of this
paper is a radiologist, so I am hopeful that we can begin to
incorporate renal volumemeasurement into our reports of patients
in whom renal artery intervention is being contemplated.
We did not look at surgical revascularization in this study.
Initially, it was our intent to include surgical bypasses in this study.
Currently, we are performing many fewer renal artery bypasses
than in years past, and most of those bypasses are for purposes of
aortic debranching. I would be uncomfortable speculating on the
utility of kidney volume based on such a small subset of patients.
Dr John Blebea (Cleveland, Ohio). The volumemeasurement
calculations seem rather simplistic, as the kidney is not a rectangle.
I have two questions: First, what is the reproducibility of these
volume measurements? The results could easily change depending
on the caliper location, especially of the depth measurements.
Second, were your volume categories and measurement cutoffs
established at the beginning of the study, or did you calculate them
and arbitrarily decide on the particular cutoff values of 150 and 75
after the data were obtained?
Dr Modrall. You are correct. There is subjectivity, although
minimal. Multiple recordings were obtained for each measure-
ment, and there was 5% variation. That is an amount of inter-
measurement variability that I believe makes this technique reason-
ably reproducible.
In terms of the cutoffs, those were based on an assessment of
the graph representing increments of kidney volumes and the
respective blood pressure response rate. Based on those data, the
150 cm3 threshold appeared to be the most appropriate cutoff.
t
dI will note that while we have suggested three clinical predic-
ors and a kidney volume of 150 cm3, it is our intent to validate
hese recommendations in an entirely separate population. I think
e will be more confident in our recommendations with further
alidation.
Dr Vikram Paruchuri (Boston, Mass). Question 1: I would
ssume that considering the age of the cohort, many patients in the
tudy had coronary artery disease, hypertension, or benign prostate
yperplasia. Were diuretics, nitrates, -blockers included in the
ubgroup of patients when you took in the total number of
ntihypertensive medications pre- and postintervention? My sec-
nd question is, large kidneys and increased kidney volume have
een seen in patients with diabetes mellitus and interstitial kidney
isease. Do you know what proportion of your patients had
nterstitial kidney disease and diabetes mellitus?
Dr Modrall. I believe that the proportion with diabetes was
bout 35%. In each case, we attempted to exclude those patients
ith another obvious source for the hypertension or renal insuffi-
iency, such as nephritis. There was one case of nephritis that was
xcluded from the study.
In terms of what medications were included, we struggled
ith this problem. Ultimately, we elected to include all medica-
ions which may impact blood pressure, including diuretics and
itrates. While they may not be primarily prescribed for the pur-
ose of blood pressure control, they clearly have an impact on
lood pressure.
Dr Gregory Moneta (Portland, Ore). As pointed out, the
ngioplasty and Stenting for Renal Artery Lesions (ASTRAL)
rial was largely negative and previous individual case series
xamining renal artery stenting have been largely positive. Your
ase series is, however, also largely negative to my interpreta-
ion. It’s very popular to trash the ASTRAL trial. But, your
eries also indicates the futility of renal artery stenting in many
atients. So, what should we do now? Based on your results and
nterpretation of ASTRAL, has the number of renal artery stents
ecreased in your institution?
Dr Modrall. How do we reconcile the ASTRAL trial with
hese single-center trials? Our data on the blood pressure response
ates based on the number of antihypertensive medications alone
uggest that the entry criteria for the ASTRAL trial and for the
ardiovascular Outcomes in Renal Atherosclerotic Lesions
CORAL) trial were overly liberal. For instance, the CORAL trial
as permitted inclusion of patients with two-drug hypertension. In
ur series, two-drug hypertension equates to a 7% likelihood of a
lood pressure response to renal stenting. By including patients
ith two-drug hypertension in those trials, you’re diluting the
otential benefit. The ASTRAL trial was even more less restrictive
n their enrollment criteria, so there is high likelihood that patients
ith one- and two-drug hypertension were enrolled.
Although these are important trials, they may have been
onceived prematurely. The investigators for these trials did not
ave the data to inform decisions on which patients should be
ncluded and which should not be included in the trial. As a result,
fully expect these trials to provide negative results, just as we saw
n the ASTRAL trial. I now believe we have an explanation for
hose negative results, which is perhaps why it may be appropriate
o repeat those trials with entry criteria that are informed by current
ata.
